Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 21

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 21
---
12, 2025, minus $0.0001), after deducting placement agent fees and estimated offering expenses payable by us and excluding                                                                                                                                                                                                             
 proceeds, if any, from the cash exercise of the Pre-Funded Warrants and Series L Warrants sold in this offering.                                                                                                                                                                                                                                   
 We intend to use the net proceeds from this offering to fund                                                                                                                                                                                                                                                                                       
 our development programs, for working capital and other general corporate purposes. Pending other uses, we intend to invest the net proceeds                                                                                                                                                                                                       
 to us in short-term, interest-bearing investments. We cannot predict whether the net proceeds invested will yield a favorable return.                                                                                                                                                                                                              
 See “Use of Proceeds.”                                                                                                                                                                                                                                                                                                                             |
| Risk factors              |     | An investment in our securities involves substantial risks. You should read the “Risk Factors” section starting on page 14 of this prospectus, together with all of the other information included and incorporated by reference in this prospectus, before deciding to invest in our securities.                                                  |
| Market and trading symbol |     | Our Depositary Shares are listed on the NASDAQ Capital Market under the symbol “BDRX.” We do not intend to list the Pre-Funded Warrants or Series L Warrants on any securities exchange or national recognized trading system. Without a trading market, the liquidity of the Pre-Funded Warrants and Series L Warrants will be extremely limited. |

The number of our Ordinary Shares to be outstanding immediately after this offering is calculated based upon 61,952,308,922 Ordinary Shares outstanding as of June 30, 2025, and excludes as of that date:

| · | 313,070,788 Ordinary Shares issuable upon the exercise of stock options outstanding under our equity incentive plans at a weighted-average 
 exercise price of £0.005 per share;                                                                                                        |

| · | 6 Ordinary Shares issuable upon the exercise of stock options in connection with the acquisition of DARA Bioscience, Inc. at a weighted 
 average exercise price of $981.91 per share;                                                                                            |

| · | warrants, including pre-funded warrants, exercisable for 488,720 Depositary Shares (representing 4,887,200,000 Ordinary Shares), 
 at a weighted average exercise price of $43.37 per Depositary Share; and                                                         |

| · | any warrants issuable in this offering. |

| 13 |

<div align='center'>RISK FACTORS</div>

Investing in our securities involves a high degree of risk. You